Viveve Medical (NASDAQ: VIVE) is one of 81 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare Viveve Medical to related businesses based on the strength of its risk, institutional ownership, dividends, profitability, earnings, analyst recommendations and valuation.
This is a breakdown of current ratings and recommmendations for Viveve Medical and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Viveve Medical Competitors||266||1865||3337||108||2.59|
Viveve Medical presently has a consensus target price of $10.50, indicating a potential upside of 110.42%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.39%. Given Viveve Medical’s stronger consensus rating and higher probable upside, research analysts plainly believe Viveve Medical is more favorable than its rivals.
Valuation and Earnings
This table compares Viveve Medical and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Viveve Medical||$7.14 million||-$20.11 million||-2.32|
|Viveve Medical Competitors||$2.13 billion||$229.91 million||-32.44|
Viveve Medical’s rivals have higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Viveve Medical has a beta of -0.59, indicating that its stock price is 159% less volatile than the S&P 500. Comparatively, Viveve Medical’s rivals have a beta of 0.92, indicating that their average stock price is 8% less volatile than the S&P 500.
This table compares Viveve Medical and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Viveve Medical Competitors||-311.66%||-32.15%||-11.40%|
Insider & Institutional Ownership
65.6% of Viveve Medical shares are held by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 35.1% of Viveve Medical shares are held by insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Viveve Medical Company Profile
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.